article Open AccessTop 1% cited

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Annals of Oncology · 2018 · Vol. 29(6) · pp. 1437–1444

Lisa Derosa(Université Paris-Sud)Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center)Marco Spaziano(McGill University)Darragh Halpenny(Memorial Sloan Kettering Cancer Center)Marine Fidelle(Université Paris-Sud)Hira Rizvi(Memorial Sloan Kettering Cancer Center)Niamh M. Long(Memorial Sloan Kettering Cancer Center)Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center)Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center)Jamie E. Chaft(Memorial Sloan Kettering Cancer Center)J.A. Rouche(Institut Gustave Roussy)Laurence Zitvogel(Université Paris-Sud)Gérard Zalcman(Université Claude Bernard Lyon 1)Laurence Albigès(Université Paris-Sud)Bernard Escudier(Institut Gustave Roussy)Bertrand Routy✉(Université Paris-Sud)

View via DOI Full-text PDF

Abstract

ATB were associated with reduced clinical benefit from ICI in RCC and NSCLC. Modulatation of ATB-related dysbiosis and gut microbiota composition may be a strategy to improve clinical outcomes with ICI.

Cancer Immunotherapy and Biomarkers Neutropenia and Cancer Infections Pancreatic and Hepatic Oncology ResearchMedicineInternal medicineHazard ratioLung cancerGastroenterologyRenal cell carcinomaCancerOncologyConfidence interval

MeSH terms

Antineoplastic Agents, ImmunologicalNivolumabAgedAnti-Bacterial AgentsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellFemaleFollow-Up StudiesHumansImmunotherapyKidney NeoplasmsLung NeoplasmsMalePrognosisSurvival Rate